HomeStocks › What "undervalued" means

What does it mean for a stock to be undervalued?

It means something specific and checkable: the fair value a discounted-cash-flow model works out from a company's own filed accounts sits above what the market is paying. Below, that calculation is worked end to end on 3 companies — every assumption, every year, every step from cash flow to a per-share number.

These are worked examples of the method, chosen to show it on different kinds of business. They are not a selection of what to own, not ranked against each other, and not the output of a search for the cheapest shares — the same working is published for every company on this site. A gap between a model's value and the market price is a starting point for questions, not a verdict: it can mean the market is missing something, or that the model's assumptions are. Everything the calculation rests on is on this page so you can judge which. Educational material, not investment advice, and not a price target.

Mahindra and Mahindra Tata Consultancy Services ZYDUS LIFESCIENCES
1Worked example

Mahindra and Mahindra

Automobile and Auto Components · Passenger Cars & Utility Vehicles
Model value
₹7,670.78
Market price
₹3,070
Gap
+150%
WACC
11.79%
Horizon
7 yr
Market price ₹3,070 Model value ₹7,670.78
Show the full DCF workingHide the working
Mahindra and Mahindra — DCF valuation workpaper
FCFF method · Base period: TTM · Horizon: 7 yr · All figures in ₹ crore unless noted · Scenario: BASE
↔ The projection table scrolls sideways — the line-item column stays put.

The model values one share at ₹7,670.78 against a market price of ₹3,070. That headline is the probability-weighted average of a bull, base and bear case; the base case alone comes to ₹7,329.58. Cash flows are projected for 7 years from a TTM base and discounted at 11.79%, with growth beyond that held at 6.8%.

01 Cost of capital (WACC)

ComponentValue
10-yr G-Sec yieldmarket6.78%
Less: India sovereign default spreadmarket(2.00%)
Risk-free rate (default-free, used in CAPM)a4.78%
Equity risk premiummarketb6.48%
Betamarketc1.26
Size premiums0.00%
Cost of equity (a + c×b + s)D12.95%
Cost of debt (pre-tax)marketE11.84%
Equity weight (E/V)F72.6%
Debt weight (D/V)G27.4%
Tax ratehistoricalh26.2%
WACC = D×F + E×(1−h)×GJ11.79%

The discount rate. Every future rupee below is discounted at this.

02 Key assumptions

AssumptionBasis / formulaValue
Revenue growth (seed)historicalBlended seed: median YoY + 3y / 5y CAGRBlended seed: median YoY + 3y / 5y CAGR18.6%
↳ CAGR cross-check (3y / 5y / full)for referencefor reference17.9% / 21.7% / 9.9%
EBITDA marginhistoricalavg of last 3 fiscal yearsavg of last 3 fiscal years18.6%
D&A (% of revenue)historicalΣ(D&A_i ÷ Revenue_i) ÷ nΣ(D&A_i ÷ Revenue_i) ÷ n3.6%
Capex (% of revenue)historicalΣ(Capex_i ÷ Revenue_i) ÷ nΣ(Capex_i ÷ Revenue_i) ÷ n5.9%
Net working capital — level (NWC ÷ revenue)historical(Receivables + Inventory − Payables) ÷ Revenue(Receivables + Inventory − Payables) ÷ Revenue-3.4%
Terminal growthmarketmin(nominal 10Y G-Sec anchor, WACC − 3.0%, near-term growth)min(nominal 10Y G-Sec anchor, WACC − 3.0%, near-term growth)6.8%
Effective tax ratehistoricalAvg effective rate from the P&L (recent years), bounded 15–35%Avg effective rate from the P&L (recent years), bounded 15–35%26.2%

Each of these is derived from the company's own reported history or from observable market data — never from management guidance or a broker forecast.

03 Free cash flow to firm (FCFF) projection

Line item (₹ crore)FY1FY2FY3FY4FY5FY6FY7
Revenue growth18.6%18.6%16.2%13.8%11.5%9.1%6.8%
Revenue2,50,5982,97,1003,45,2333,93,0334,38,1944,78,2245,10,648
EBITDA46,51355,44564,77874,14483,10891,18497,883
Less: Depreciation & amortisation(9,078)(10,841)(12,687)(14,547)(16,334)(17,952)(19,303)
= EBIT37,43544,60552,09059,59766,77473,23278,580
Less: Tax(9,827)(11,709)(13,674)(15,644)(17,528)(19,223)(20,627)
= NOPAT (debt-free net income)27,60932,89638,41643,95349,24654,00957,953
Add: Depreciation & amortisation9,07810,84112,68714,54716,33417,95219,303
Less: Capital expenditure(14,856)(16,830)(18,647)(20,193)(21,358)(22,049)(22,198)
Working capital movement1,3394,0634,9215,7046,3226,6866,713
= Free cash flow to firm23,16930,97037,37844,01150,54456,59761,771
Discount factor (mid-year)0.9460.8460.7570.6770.6060.5420.485
Present value of FCFF21,91426,20228,28929,79630,60930,66129,934

FCFF = NOPAT + D&A − capex − ΔNWC · mid-year discounting convention

04 Terminal value & enterprise value

ItemValue (₹ crore)
Sum of PV of FCFF (explicit period)1,97,403
Terminal value (Gordon growth, g = 6.8%)12,36,725
PV of terminal value5,99,313
= Enterprise value7,96,717

Terminal value is 75% of enterprise value.

05 Equity value & value per share

ItemValue
Enterprise value7,96,717
Add: Net cash (cash − debt)22,657
= Equity value8,19,373
Shares outstanding (crore)111.79
= Intrinsic value per share (base case)₹7,329.58

06 Scenario summary (₹ / share)

ScenarioPer shareUpside / downside
Bull₹10,355.20+237.3%
Base₹7,329.58+138.7%
Bear₹3,740.73+21.8%

07 Probability-weighted fair value

The headline figure is not the base case — it is the probability-weighted average of all three scenarios: Σ (scenario value × probability).

ScenarioPer share (₹)ProbabilityContribution (₹)
Bull₹10,355.2035.0%₹3,624.32
Base₹7,329.5845.0%₹3,298.31
Bear₹3,740.7320.0%₹748.15
= Probability-weighted fair value100.0%₹7,670.78

vs current price ₹3,070 → +150%

Prior: base case is the single most likely outcome (25/50/25). Growth seed 18.6% (>15%) with improving margins → +10pp bull, −5pp bear.

See the full Mahindra and Mahindra valuation, ratios and ten-year history →
2Worked example

TCS

Information Technology · Computers - Software & Consulting
Model value
₹3,444.03
Market price
₹2,189
Gap
+57%
WACC
10.23%
Horizon
7 yr
Market price ₹2,189 Model value ₹3,444.03
Show the full DCF workingHide the working
TCS — DCF valuation workpaper
FCFF method · Base period: TTM · Horizon: 7 yr · All figures in ₹ crore unless noted · Scenario: BASE
↔ The projection table scrolls sideways — the line-item column stays put.

The model values one share at ₹3,444.03 against a market price of ₹2,189. That headline is the probability-weighted average of a bull, base and bear case; the base case alone comes to ₹3,546.47. Cash flows are projected for 7 years from a TTM base and discounted at 10.23%, with growth beyond that held at 5.5%.

01 Cost of capital (WACC)

ComponentValue
10-yr G-Sec yieldmarket6.78%
Less: India sovereign default spreadmarket(2.00%)
Risk-free rate (default-free, used in CAPM)a4.78%
Equity risk premiummarketb6.48%
Betamarketc0.84
Size premiums0.00%
Cost of equity (a + c×b + s)D10.23%
Cost of debt (pre-tax)marketE8.50%
Equity weight (E/V)F100.0%
Debt weight (D/V)G0.0%
Tax ratehistoricalh25.3%
WACC = D×F + E×(1−h)×GJ10.23%

The discount rate. Every future rupee below is discounted at this.

02 Key assumptions

AssumptionBasis / formulaValue
Revenue growth (seed)historicalBlended seed: median YoY + 3y / 5y CAGRBlended seed: median YoY + 3y / 5y CAGR6.6%
↳ CAGR cross-check (3y / 5y / full)for referencefor reference5.8% / 10.2% / 9.0%
EBITDA marginhistoricalavg of last 3 fiscal yearsavg of last 3 fiscal years26.8%
D&A (% of revenue)historicalΣ(D&A_i ÷ Revenue_i) ÷ nΣ(D&A_i ÷ Revenue_i) ÷ n2.1%
Capex (% of revenue)historicalΣ(Capex_i ÷ Revenue_i) ÷ nΣ(Capex_i ÷ Revenue_i) ÷ n1.7%
Net working capital — level (NWC ÷ revenue)historical(Receivables + Inventory − Payables) ÷ Revenue(Receivables + Inventory − Payables) ÷ Revenue19.8%
Terminal growthmarketmin(nominal 10Y G-Sec anchor, WACC − 3.0%, near-term growth)min(nominal 10Y G-Sec anchor, WACC − 3.0%, near-term growth)5.5%
Effective tax ratehistoricalAvg effective rate from the P&L (recent years), bounded 15–35%Avg effective rate from the P&L (recent years), bounded 15–35%25.3%

Each of these is derived from the company's own reported history or from observable market data — never from management guidance or a broker forecast.

03 Free cash flow to firm (FCFF) projection

Line item (₹ crore)FY1FY2FY3FY4FY5FY6FY7
Revenue growth6.6%6.6%6.4%6.2%6.0%5.8%5.5%
Revenue2,94,1483,13,6493,33,7603,54,4323,75,6133,97,2414,19,248
EBITDA78,92484,39990,06895,9201,01,9421,08,1181,14,431
Less: Depreciation & amortisation(6,201)(6,281)(6,332)(6,351)(6,334)(6,280)(6,187)
= EBIT72,72478,11883,73689,56995,6071,01,8371,08,245
Less: Tax(18,428)(19,795)(21,219)(22,697)(24,227)(25,806)(27,429)
= NOPAT (debt-free net income)54,29558,32362,51766,87271,38076,03280,815
Add: Depreciation & amortisation6,2016,2816,3326,3516,3346,2806,187
Less: Capital expenditure(4,961)(5,289)(5,629)(5,977)(6,334)(6,699)(7,070)
Working capital movement(3,626)(3,866)(3,987)(4,098)(4,199)(4,288)(4,363)
= Free cash flow to firm51,91055,44859,23463,14867,18171,32675,569
Discount factor (mid-year)0.9530.8640.7840.7110.6450.5850.531
Present value of FCFF49,44347,91146,43244,90643,34141,74440,123

FCFF = NOPAT + D&A − capex − ΔNWC · mid-year discounting convention

04 Terminal value & enterprise value

ItemValue (₹ crore)
Sum of PV of FCFF (explicit period)3,13,901
Terminal value (Gordon growth, g = 5.5%)17,00,203
PV of terminal value9,02,718
= Enterprise value12,16,619

Terminal value is 74% of enterprise value.

05 Equity value & value per share

ItemValue
Enterprise value12,16,619
Add: Net cash (cash − debt)67,203
= Equity value12,83,822
Shares outstanding (crore)362.00
= Intrinsic value per share (base case)₹3,546.47

06 Scenario summary (₹ / share)

ScenarioPer shareUpside / downside
Bull₹4,088.92+86.8%
Base₹3,546.47+62.0%
Bear₹2,594.26+18.5%

07 Probability-weighted fair value

The headline figure is not the base case — it is the probability-weighted average of all three scenarios: Σ (scenario value × probability).

ScenarioPer share (₹)ProbabilityContribution (₹)
Bull₹4,088.9225.0%₹1,022.23
Base₹3,546.4750.0%₹1,773.23
Bear₹2,594.2625.0%₹648.57
= Probability-weighted fair value100.0%₹3,444.03

vs current price ₹2,189 → +57%

Prior: base case is the single most likely outcome (25/50/25). Weights renormalised to sum to 100%.

See the full Tata Consultancy Services valuation, ratios and ten-year history →
3Worked example

ZYDUS LIFESCIENCES

Healthcare · Pharmaceuticals
Model value
₹2,466.17
Market price
₹1,108
Gap
+123%
WACC
9.20%
Horizon
7 yr
Market price ₹1,108 Model value ₹2,466.17
Show the full DCF workingHide the working
ZYDUS LIFESCIENCES — DCF valuation workpaper
FCFF method · Base period: TTM · Horizon: 7 yr · All figures in ₹ crore unless noted · Scenario: BASE
↔ The projection table scrolls sideways — the line-item column stays put.

The model values one share at ₹2,466.17 against a market price of ₹1,108. That headline is the probability-weighted average of a bull, base and bear case; the base case alone comes to ₹2,599.41. Cash flows are projected for 7 years from a TTM base and discounted at 9.20%, with growth beyond that held at 6.2%.

01 Cost of capital (WACC)

ComponentValue
10-yr G-Sec yieldmarket6.78%
Less: India sovereign default spreadmarket(2.00%)
Risk-free rate (default-free, used in CAPM)a4.78%
Equity risk premiummarketb6.48%
Betamarketc0.74
Size premiums0.00%
Cost of equity (a + c×b + s)D9.58%
Cost of debt (pre-tax)marketE7.17%
Equity weight (E/V)F90.4%
Debt weight (D/V)G9.6%
Tax ratehistoricalh21.7%
WACC = D×F + E×(1−h)×GJ9.20%

The discount rate. Every future rupee below is discounted at this.

02 Key assumptions

AssumptionBasis / formulaValue
Revenue growth (seed)historicalBlended seed: median YoY + 3y / 5y CAGRBlended seed: median YoY + 3y / 5y CAGR14.8%
↳ CAGR cross-check (3y / 5y / full)for referencefor reference16.3% / 12.4% / 10.8%
EBITDA marginhistoricalavg of last 3 fiscal yearsavg of last 3 fiscal years29.7%
D&A (% of revenue)historicalΣ(D&A_i ÷ Revenue_i) ÷ nΣ(D&A_i ÷ Revenue_i) ÷ n4.3%
Capex (% of revenue)historicalΣ(Capex_i ÷ Revenue_i) ÷ nΣ(Capex_i ÷ Revenue_i) ÷ n7.6%
Net working capital — level (NWC ÷ revenue)historical(Receivables + Inventory − Payables) ÷ Revenue(Receivables + Inventory − Payables) ÷ Revenue30.2%
Terminal growthmarketmin(nominal 10Y G-Sec anchor, WACC − 3.0%, near-term growth)min(nominal 10Y G-Sec anchor, WACC − 3.0%, near-term growth)6.2%
Effective tax ratehistoricalAvg effective rate from the P&L (recent years), bounded 15–35%Avg effective rate from the P&L (recent years), bounded 15–35%21.7%

Each of these is derived from the company's own reported history or from observable market data — never from management guidance or a broker forecast.

03 Free cash flow to firm (FCFF) projection

Line item (₹ crore)FY1FY2FY3FY4FY5FY6FY7
Revenue growth14.8%14.8%13.1%11.3%9.6%7.9%6.2%
Revenue32,81737,66842,58847,42151,98956,10459,583
EBITDA9,75011,28612,86714,44715,96917,37418,600
Less: Depreciation & amortisation(1,413)(1,634)(1,861)(2,087)(2,304)(2,504)(2,678)
= EBIT8,3379,65211,00612,36013,66514,87015,922
Less: Tax(1,810)(2,095)(2,389)(2,683)(2,967)(3,228)(3,457)
= NOPAT (debt-free net income)6,5277,5568,6179,67610,69811,64112,466
Add: Depreciation & amortisation1,4131,6341,8612,0872,3042,5042,678
Less: Capital expenditure(2,501)(2,717)(2,898)(3,033)(3,112)(3,129)(3,080)
Working capital movement(1,276)(1,180)(1,126)(1,027)(882)(693)(468)
= Free cash flow to firm4,1635,2946,4547,7039,00810,32311,596
Discount factor (mid-year)0.9570.8760.8020.7350.6730.6160.564
Present value of FCFF3,9844,6395,1795,6616,0626,3626,545

FCFF = NOPAT + D&A − capex − ΔNWC · mid-year discounting convention

04 Terminal value & enterprise value

ItemValue (₹ crore)
Sum of PV of FCFF (explicit period)38,431
Terminal value (Gordon growth, g = 6.2%)3,94,810
PV of terminal value2,22,813
= Enterprise value2,61,245

Terminal value is 85% of enterprise value.

05 Equity value & value per share

ItemValue
Enterprise value2,61,245
Less: Net debt (debt − cash)(1,823)
= Equity value2,59,421
Shares outstanding (crore)99.80
= Intrinsic value per share (base case)₹2,599.41

06 Scenario summary (₹ / share)

ScenarioPer shareUpside / downside
Bull₹3,589.19+224.1%
Base₹2,599.41+134.7%
Bear₹1,076.66-2.8%

07 Probability-weighted fair value

The headline figure is not the base case — it is the probability-weighted average of all three scenarios: Σ (scenario value × probability).

ScenarioPer share (₹)ProbabilityContribution (₹)
Bull₹3,589.1925.0%₹897.30
Base₹2,599.4150.0%₹1,299.70
Bear₹1,076.6625.0%₹269.17
= Probability-weighted fair value100.0%₹2,466.17

vs current price ₹1,108 → +123%

Prior: base case is the single most likely outcome (25/50/25). Weights renormalised to sum to 100%.

See the full ZYDUS LIFESCIENCES valuation, ratios and ten-year history →

Questions

What does it mean for a stock to be undervalued?

On this page it means one specific, measurable thing: the fair value our discounted-cash-flow model works out from the company's own filed accounts sits above the current market price. It is not a claim that the share is cheap or a suggestion to buy it — a gap can equally mean the market knows something the model's assumptions do not. Every assumption behind every number is shown here so the gap can be examined rather than taken on trust.

How is the fair value calculated?

By discounted cash flow. We forecast free cash flow to the firm from the company's own record, discount each year at its weighted average cost of capital, add a terminal value for the years beyond, subtract net debt and divide by the shares outstanding. That is done three times — a bull, a base and a bear case — and the headline figure is the probability-weighted average of the three. The whole build-up is printed below for each company.

Why is the headline figure different from the base case?

Because the headline is probability-weighted. The base case is the single most likely outcome, but it is not the only one, so the bull and bear cases are valued too and each is weighted by how likely it is. A point estimate that ignores the distribution around it overstates how precise a valuation can be. Both figures — the base case and the weighted headline — are shown.

Is this investment advice?

No. This is an educational illustration of a valuation method, not a recommendation. A fair value is an estimate that is only as good as its assumptions, and small changes to growth, margins or the discount rate move it a great deal. Do your own research and consider a SEBI-registered investment adviser before acting.